Nowe metody i perspektywy leczenia farmakologicznego otyłości
Słowa kluczowe:
farmakoterapia otyłości w Polsce, farmakoterapia otyłości na świecie, nieinwazyjne leczenie otyłości, semaglutyd, fentermina-topiramat, lokaseryna, SGLT2, tirzepatyd, perspektywy faramkoterapii otyłościStreszczenie
Otyłość, uznana za chorobę, jest problemem społecznym i ekonomicznym określanym mianem epidemii XXI wieku. Patogeneza otyłości jest wieloczynnikowa. W jej skład wchodzą czynniki genetyczne, metaboliczne oraz środowiskowe. Farmakoterapia jest metodą leczenia otyłości stosowaną przede wszystkim u chorych z BMI ≥30 kg/m2, u których w wyniku postępowania dietetycznego i behawioralnego nie uzyskano istotnej redukcji masy ciała. Aktualnie na terenie Unii Europejskiej dostępne są 4 leki zarejestrowane przez Europejską Agencję Leków (EMA) ze wskazaniem do leczenia otyłości: orlistat, preparat złożony z chlorowodorku naltreksonu i chlorowodorku bupropionu oraz dwa analogi ludzkiego peptydu glukagonopodobnego 1 (GLP-1): liraglutyd i semaglutyd. W poniższej pracy dokonano przeglądu dotychczasowych możliwości leczenia farmakologicznego otyłości w Polsce i na świecie oraz ich najnowsze innowacje i perspektywy rozwoju.
Rozdziały
-
Nowe metody i perspektywy leczenia farmakologicznego otyłości
Bibliografia
World Health Organisation. Obesity and Overweight. World Health Organisation. Published June 9, 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity. 2018;27(1):7-9. doi:https://doi.org/10.1002/oby.22378
Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. European Journal of Public Health. 2017;28(2):295-300. doi:https://doi.org/10.1093/eurpub/ckx143
Stepaniak U, Micek A, Waśkiewicz A, et al. Prevalence of general and abdominal obesity and overweight among adults in Poland. Results of the WOBASZ II study (2013–2014) and comparison with the WOBASZ study (2003–2005). Polish Archives of Internal Medicine. Published online August 18, 2016. doi:https://doi.org/10.20452/pamw.3499
Obesity rate by body mass index (BMI) (sdg_02_10). ec.europa.eu. Accessed February 22, 2023. https://ec.europa.eu/eurostat/cache/metadata/en/sdg_02_10_esmsip2.htm
NEEL JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”?. American journal of human genetics. 1962;14(4):353-362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932342/
Hales CN, Barker DJ. The thrifty phenotype hypothesis. British medical bulletin. 2001;60(1):5-20. doi:https://doi.org/10.1093/bmb/60.1.5
Jéquier E. Pathways to obesity. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2002;26 Suppl 2:S12-17. doi:https://doi.org/10.1038/sj.ijo.0802123
Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. The Lancet. 2016;388(10046):776-786. doi:https://doi.org/10.1016/s0140-6736(16)30175-1
Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. Published online May 4, 2016:i2156. doi:https://doi.org/10.1136/bmj.i2156
Zalecenia PTLO 2022. Rozdział 10. Farmakoterapia otyłości. www.mp.pl. Accessed February 22, 2023. https://www.mp.pl/nadwaga-i-otylosc/wytyczne/303535
Sombra LRS, Anastasopoulou C. Pharmacologic Therapy For Obesity. PubMed. Published 2022. https://www.ncbi.nlm.nih.gov/books/NBK562269/
Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2003;27(1):155-161. doi:https://doi.org/10.2337/diacare.27.1.155
Li Z, Maglione M, Tu W, et al. Meta-Analysis: Pharmacologic Treatment of Obesity. Annals of Internal Medicine. 2005;142(7):532. doi:https://doi.org/10.7326/0003-4819-142-7-200504050-00012
LeBlanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2011;155(7):434. doi:https://doi.org/10.7326/0003-4819-155-7-201110040-00006
Olszanecka-Glinianowicz M, Zakład P, Zdrowia, Otyłości L, Patofizjologii K. Choroby Serca i Naczyń. 2016;13:333-348. Accessed February 22, 2023. https://journals.viamedica.pl/choroby_serca_i_naczyn/article/download/50197/37091
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity. 2011;36(6):843-854. doi:https://doi.org/10.1038/ijo.2011.158
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013;37(11):1443-1451. doi:https://doi.org/10.1038/ijo.2013.120
19. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-322. doi:https://doi.org/10.1056/nejmoa1603827
Yanovski SZ, Yanovski JA. Progress in Pharmacotherapy for Obesity. JAMA. 2021;326(2):129. doi:https://doi.org/10.1001/jama.2021.9486
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021;384(11). doi:https://doi.org/10.1056/NEJMoa2032183
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10278):971-984. doi:https://doi.org/10.1016/s0140-6736(21)00213-0
Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. doi:https://doi.org/10.1001/jama.2021.1831
24. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:https://doi.org/10.1001/jama.2021.3224
Kardiologia po Dyplomie - Farmakoterapia we wspomaganiu leczenia otyłości – aktualn... podyplomie.pl. Accessed February 22, 2023. https://podyplomie.pl/kardiologia/25123
Jf M, Ac M, Em W, Lj D. Comparison of continuous and intermittent anorectic therapy in obesity. British medical journal. 1968;1(5588). doi:https://doi.org/10.1136/bmj.1.5588.352
Via Medica Journals. journals.viamedica.pl. Accessed February 22, 2023. https://journals.viamedica.pl/endokrynologia
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9774):1341-1352. doi:https://doi.org/10.1016/s0140-6736(11)60205-5
Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. The American Journal of Clinical Nutrition. 2011;95(2):297-308. doi:https://doi.org/10.3945/ajcn.111.024927
Salari N, Jafari S, Darvishi N, et al. The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetology & Metabolic Syndrome. Published online October 18, 2021. doi:https://doi.org/10.1186/s13098-021-00733-5
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. Published online June 4, 2022. doi:https://doi.org/10.1056/nejmoa2206038
Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov. Published September 2, 2021. https://clinicaltrials.gov/ct2/show/NCT04255433
Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity. 2013;22(4):1042-1049. doi:https://doi.org/10.1002/oby.20663
Shi Y, Si Y, Fu R, et al. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials. Endokrynologia Polska. Published online January 31, 2022. doi:https://doi.org/10.5603/ep.a2021.0102
Greenway FL, Aronne LJ, Raben A, et al. A Randomized, Double‐Blind, Placebo‐Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity. 2018;27(2):205-216. doi:https://doi.org/10.1002/oby.22347
Gras J. Cetilistat for the treatment of obesity. Drugs of Today. 2013;49(12):755. doi:https://doi.org/10.1358/dot.2013.49.12.2099318
Jabbour SA, Frías JP, Ahmed A, et al. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care. 2020;43(10):2528-2536. doi:https://doi.org/10.2337/dc19-1350
Opublikowane
7 czerwca 2023
Prawa autorskie (c) 2023 Natalia Nafalska, Małgorzata Stopyra, Radosław Szydłowski, Patrycja Pabis
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
